Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease

Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease

Source: 
Pharmaceutical Business Review
snippet: 


Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for teprotumumab, an investigational medicine for the treatment of active thyroid eye disease (TED), and granted it Priority Review designation.